Pfizer Total Liabilities 2010-2024 | PFE

Pfizer total liabilities from 2010 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
  • Pfizer total liabilities for the quarter ending September 30, 2024 were $126.918B, a 7.72% increase year-over-year.
  • Pfizer total liabilities for 2023 were $137.213B, a 35.47% increase from 2022.
  • Pfizer total liabilities for 2022 were $101.288B, a 2.62% decline from 2021.
  • Pfizer total liabilities for 2021 were $104.013B, a 14.61% increase from 2020.
Pfizer Annual Total Liabilities
(Millions of US $)
2023 $137,213
2022 $101,288
2021 $104,013
2020 $90,756
2019 $104,148
2018 $95,664
2017 $100,141
2016 $111,776
2015 $102,384
2014 $95,944
2013 $95,481
2012 $104,120
2011 $105,381
2010 $106,749
2009 $122,503
Pfizer Quarterly Total Liabilities
(Millions of US $)
2024-09-30 $126,918
2024-06-30 $128,218
2024-03-31 $128,537
2023-12-31 $137,213
2023-09-30 $117,817
2023-06-30 $120,875
2023-03-31 $94,381
2022-12-31 $101,288
2022-09-30 $102,459
2022-06-30 $107,821
2022-03-31 $101,155
2021-12-31 $104,013
2021-09-30 $103,221
2021-06-30 $99,605
2021-03-31 $89,953
2020-12-31 $90,756
2020-09-30 $113,487
2020-06-30 $113,370
2020-03-31 $100,998
2019-12-31 $104,148
2019-09-30 $105,051
2019-06-30 $96,274
2019-03-31 $96,263
2018-12-31 $95,664
2018-09-30 $96,174
2018-06-30 $94,856
2018-03-31 $94,071
2017-12-31 $100,141
2017-09-30 $111,041
2017-06-30 $109,863
2017-03-31 $110,038
2016-12-31 $111,776
2016-09-30 $114,829
2016-06-30 $107,592
2016-03-31 $99,582
2015-12-31 $102,384
2015-09-30 $103,743
2015-06-30 $93,698
2015-03-31 $93,053
2014-12-31 $95,944
2014-09-30 $93,057
2014-06-30 $95,656
2014-03-31 $93,740
2013-12-31 $95,481
2013-09-30 $97,167
2013-06-30 $100,358
2013-03-31 $104,571
2012-12-31 $104,120
2012-09-30 $100,488
2012-06-30 $102,881
2012-03-31 $102,006
2011-12-31 $105,381
2011-09-30 $105,602
2011-06-30 $106,936
2011-03-31 $104,423
2010-12-31 $106,749
2010-09-30 $103,347
2010-06-30 $104,193
2010-03-31 $105,031
2009-12-31 $122,503
2009-09-30 $75,044
2009-06-30 $76,104
2009-03-31 $62,491
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $142.241B $58.496B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94